Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurocrine BiosciencesFRA:NB3 +3.50%93 EV-to-EBIT is 18.94 as of Aug. 14, 2026, which is 52% below its 10-year median of 39.11. GuruFocus rates FRA:NB3 with a GF Score™ of 93/100 and a GF Value™ of €174.90 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 682 Drug Manufacturers companies, Neurocrine Biosciences ranks worse than 55.28% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Neurocrine Biosciences's Enterprise Value for the quarter that ended in Jun. 2026 was €15,032 Mil.
Neurocrine Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €703 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NB3 vs VTRS, UTHR, ELAN: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's EV-to-EBIT falls into.
Neurocrine Biosciences's current Enterprise Value is €13,310 Mil.
Neurocrine Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €703 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (FRA:NB3) has a EV-to-EBIT of 18.94 as of Aug. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Neurocrine Biosciences and its competitors. This is 52% below median its historical median of 39.11. According to the industry distribution chart, Neurocrine Biosciences ranks #377 out of 682 companies in the Drug Manufacturers industry, placing it in the top 55.3%.
Is Neurocrine Biosciences' EV-to-EBIT too high?
Neurocrine Biosciences' current EV-to-EBIT of 18.94 is 52% below median its 10-year median of 39.11. The Drug Manufacturers industry median EV-to-EBIT is 15.86. Neurocrine Biosciences' value of 18.94 is 19.5% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #377 out of 682 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Neurocrine Biosciences has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' EV-to-EBIT compare to VTRS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #377 out of 682 companies for EV-to-EBIT. This places Neurocrine Biosciences in the lower half of its industry. The industry median EV-to-EBIT is 15.86. Neurocrine Biosciences' value of 18.94 is 19.5% above this benchmark. While the company's 10-year median is 39.11 vs. the industry median of 15.86, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current EV-to-EBIT of 18.94 is 19.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current EV-to-EBIT is 18.94, which is 52% below median its own 10-year median of 39.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Modestly Undervalued. The stock's GF Value™ is €174.90, compared to a current price of €134.55 — trading 23.1% below its estimated fair value. The current EV-to-EBIT is 18.94, which is 52% below median its 10-year median of 39.11 and 19.5% above the Drug Manufacturers industry median of 15.86. Neurocrine Biosciences' overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current EV-to-EBIT is 18.94 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €134.55 is trading 23.1% below its estimated GF Value™ of €174.90.
GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.
Key valuation signals for FRA:NB3:
EV-to-EBIT: 18.94 (52% below median its 10-year median of 39.11)
GF Value™: €174.90 vs. price of €134.55 (23.1% below fair value)
Industry Position: 19.5% above the Drug Manufacturers median (#377 of 682)
No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
93GF Score
Get the complete analysis for FRA:NB3
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NB3 has been successfully added to your 
